Edition:
United States

Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

11.84USD
15 Dec 2017
Change (% chg)

$-0.08 (-0.67%)
Prev Close
$11.92
Open
$11.85
Day's High
$11.95
Day's Low
$11.84
Volume
3,066
Avg. Vol
1,661
52-wk High
$17.50
52-wk Low
$10.44

Summary

Name Age Since Current Position

David Ebsworth

61 2014 Non-Executive Chairman of the Board

Sven Karlsson

60 2012 Chief Executive Officer, Executive Director

Kenneth Newman

2015 Chief Medical Officer

Ben Harber

2013 Company Secretary

Kenneth Cunningham

62 2015 Non-Executive Director

Vikas Sinha

53 2016 Non-Executive Director

Anders Ullman

59 2015 Non-Executive Director

Biographies

Name Description

David Ebsworth

Dr. David Raymond Ebsworth, Ph.D. has been appointed as Non-Executive Chairman of the Board of the Company effective 1 December 2014. He is an experienced pharmaceutical executive who has worked at Board and Senior Management level at a number of companies internationally. He has extensive experience of product development and life cycle management and has been involved in successful product approvals in the US and Europe. From October 2009 to August 2014, Dr Ebsworth served as Chief Executive Officer (CEO) of Vifor Pharma, based in Zürich, the Specialty Pharma division of Galenica AG Group, the leading pharmaceutical wholesaler and retailer in Switzerland. Dr. Ebsworth was also named as CEO of Galenica AG in 2011. He continues as advisor to the CEO of Vifor Pharma and Galenica Santé, the two companies which are preparing to separate out of the Galenica Group as announced in August 2014. During his tenure with the Galenica Group, its value increased from CHF 2.4 billion to CHF 5.6 billion, with, most notably, two FDA approvals and one EMA approval. Dr Ebsworth's career spans over 35 years in the global pharmaceutical industry, largely with Bayer AG covering senior management roles in Leverkusen, Germany, the US and Canada. Aside from Bayer, where he worked for over 19 years having joined as a product manager in 1983, Dr Ebsworth spent two years as Chairman of A&D Pharma-Holdings NV in Bucharest, Romania. He also served as Chief Executive Officer of Oxford Glycosciences (OGS), a biotech company listed on the LSE and NASDAQ stock exchanges, which was acquired by Celltech plc (now part of UCB) in 2003. OGS was the world leader in proteomics and had development compounds for Gaucher's disease and cancer. Dr Ebsworth has served on a number of Boards within the pharma, biotech and venture capital sectors, in the UK, Germany, the US, Austria, Italy, Israel, Netherlands, and Japan. During the past five years Dr Ebsworth has held directorships at Xention Ltd, Wilex AG and Intercell AG.

Sven Karlsson

Dr. Sven Jan-Anders Karlsson is Chief Executive Officer, Executive Director of Verona Pharma Plc. He has pharmaceutical and biotechnology R&D and corporate experience. He was formerly the CEO at S*BIO, a Singapore and US based biotechnology company focused on the discovery and development of novel small molecule anti-cancer drugs. Before S*BIO, Dr Karlsson was Executive Vice President of Pharma Global Research at Bayer Healthcare after holding senior leadership positions at Rhone-Poulenc Rorer (now Sanofi) and Astra (now AstraZeneca).

Kenneth Newman

Dr. Kenneth B. Newman, M.D., M.B.A., has been appointed as Chief Medical Officer of the Company effective January 1, 2015. Dr. Newman is an experienced pharmaceutical and biotechnology industry executive with extensive leadership experience in clinical development, including a number of orally inhaled drugs for the treatment of respiratory disease. Dr. Newman will join Verona Pharma from Mesoblast Inc (ASX: MSB), a leading regenerative medicine company, where he was Chief Development Officer and Head of Global Clinical Development. Prior to that, between 2010 and 2013, Dr. Newman was Chief Medical Officer and EVP of Acton Pharmaceuticals, where he was responsible for the clinical development and regulatory submission of two respiratory products that were subsequently approved by the FDA. Acton was sold to Meda Pharmaceuticals (STOSE: MEDA) for $135m in August 2013. From 2006 to 2009, Dr. Newman was VP, Medical Affairs at Boehringer Ingelheim, where he oversaw the Medical Affairs Department, which comprised of a number of therapeutics areas, including respiratory. From 1997-2006, Dr. Newman held a number of positions of increasing seniority within the Clinical Development and Medical Affairs Departments at Forest Laboratories (now Actavis NYSE: ACT), culminating in Executive Director, Clinical Development. Dr. Newman began his professional career as an attending physician at the National Jewish Medical and Research Center, Denver, Colorado and then the University of Cincinnati, Ohio. He was awarded an MBA from University of Cincinnati in 1998.

Ben Harber

Kenneth Cunningham

Dr. Kenneth D. Cunningham, M.D. has been appointed as Non-Executive Director of the Company, with effect from 10 September 2015. He has over 25 years’ experience in the pharmaceutical industry including leadership roles at several companies focused on developing respiratory medicines. He is currently Non-Executive Chairman of Abzena plc (AIM: ABZA) and Non-Executive Director of Xention Pharma Ltd and was Non-Executive Chairman of Prosonix Ltd ahead of its recent sale to Circassia for £100m in June 2015. Between 2008 and 2010 Dr Cunningham was at SkyePharma plc, initially as Chief Operating Officer and subsequently as Chief Executive Officer where he was deeply involved in the late stage development of flutiform® for asthma. Between 2002 and 2005 he was Chief Executive Officer of Arakis Ltd, a drug re-profiling company which was subsequently sold to Sosei (TSE: 4565) for £107m. The lead compound was then licensed to Novartis and following further development is currently under regulatory review by the FDA and is available in Europe as an orally inhaled drug for COPD under the name Seebri® and Ultibro®. Prior to this, Dr Cunningham was Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Earlier in his career, he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert. Dr Cunningham holds a Medical Degree from St Mary's, Imperial College, London University.

Vikas Sinha

Mr. Vikas Sinha serves as Non-Executive Director of the company. He has over 20 years of experience working in senior finance roles in the life sciences industry. He is currently Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), one of the world's leading rare disease companies with a market cap of approximately USD30 billion. Vikas joined Alexion in 2005 and is responsible for global financial management, information technology, corporate and strategic development, treasury, internal audit and investor relations. Prior to Alexion, Vikas spent 11 years at Bayer AG where he held various positions within the company in the United States, Canada, Japan and Germany. His last role was Vice President and Chief Financial Officer of Bayer Pharmaceuticals Corporation, USA, where he was responsible for financial management and strategic planning in North America. Prior to his time at Bayer AG, Vikas worked at ANZ Bank as a Senior Manager in Corporate Banking and at Citibank as an analyst. Vikas is a chartered accountant by training. He is a certified public accountant in the USA, and an associate member of the Institute of Chartered Accountants of India. Vikas also has a Master’s degree in Business Administration from the Asian Institute of Management in the Philippines.

Anders Ullman

Dr. Anders Ullman, M.D., Ph.D., has been appointed as Non-Executive Independent Director of the Company, with effect from 10 September 2015. He is an experienced pharmaceutical executive who has worked at Board and Senior Management level at a number of companies internationally. He has extensive experience of product development and life cycle management and has been involved in successful product approvals including two with the FDA and one with the EMA. From 2013 to 2014, Dr Ullman was Head of R&D at Baxter Biosciences, based in Vienna, Austria. From 2007 to 2013 he was EVP Head of R&D at Nycomed Pharma Pvt Limited where he led the development and approval of Daxas, the PDE4 inhibitor used to prevent COPD exacerbations. Following the sale of Nycomed to Takeda in 2011, he led the R&D transition team at Takeda Pharmaceuticals International GmbH. Prior to his time at Nycomed, Dr Ullman was Head of R&D at Biovitrum AB and EVP Global Product Development at Bayer Healthcare while earlier in his career he held a number of roles of increasing responsibility in AstraZeneca exiting as VP Global Clinical Function.

Basic Compensation

Name Fiscal Year Total

David Ebsworth

7,207

Sven Karlsson

390,457

Kenneth Newman

--

Ben Harber

--

Kenneth Cunningham

--

Vikas Sinha

--

Anders Ullman

--
As Of  30 Dec 2014